A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
S1320: A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E K Mutant Melanoma
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
A Pilot Study of Telmisartan (Micardis) for the Prevention of Acute Graft Versus Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation
A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)
Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma
“Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702 BMT CTN 0702 Long-Term Follow-Up
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers